Roni Mamluk - 05 Aug 2021 Form 4 Insider Report for CHIASMA, INC

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 05 Aug 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Aug 2021, 18:00:07 UTC
Next SEC filing: 05 Jan 2022
Source filing: View source filing
Reporting owner signature: /s/ Lee G. Giguere, Attorney-in-Fact

Key filing fact

Roni Mamluk filed Form 4 for CHIASMA, INC on 05 Aug 2021.

Key facts

This page summarizes Roni Mamluk's Form 4 filing for CHIASMA, INC.
8 reported transactions and 8 derivative rows are listed below.
Accepted by SEC: 05 Aug 2021, 18:00.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CHMA transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -225,689
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 05 Aug 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 225,689
Exercise price: $3.29
Footnotes: F1, F2

CHMA transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -213,345
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 05 Aug 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 213,345
Exercise price: $5.57
Footnotes: F1, F2

CHMA transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -40,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 05 Aug 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 40,000
Exercise price: $9.93
Footnotes: F2

CHMA transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -42,019
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 05 Aug 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 42,019
Exercise price: $1.85
Footnotes: F2

CHMA transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -26,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 05 Aug 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 26,000
Exercise price: $1.35
Footnotes: F2

CHMA transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -13,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 05 Aug 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,000
Exercise price: $1.45
Footnotes: F2

CHMA transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -13,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 05 Aug 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,000
Exercise price: $7.98
Footnotes: F1, F2

CHMA transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -13,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 05 Aug 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,000
Exercise price: $5.81
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Roni Mamluk is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time").

Footnote F2

At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.